Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Gilead Sciences's share price for the quarter that ended in Dec. 2023 was ARS19770. Gilead Sciences's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 1,246 Mil. Therefore, Gilead Sciences's market cap for the quarter that ended in Dec. 2023 was ARS24,634,211 Mil.
Gilead Sciences's quarterly market cap
increased
from Jun. 2023 (ARS12,319,113 Mil) to Sep. 2023 (ARS19,324,136 Mil) and
increased
from Sep. 2023 (ARS19,324,136 Mil) to Dec. 2023 (ARS24,634,211 Mil).
Gilead Sciences's annual market cap
increased
from Dec. 2021 (ARS4,639,800 Mil) to Dec. 2022 (ARS9,022,669 Mil) and
increased
from Dec. 2022 (ARS9,022,669 Mil) to Dec. 2023 (ARS24,634,211 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Gilead Sciences's Enterprise Value for Today is ARS86,696,073 Mil.
Gilead Sciences Market Cap Historical Data
The historical data trend for Gilead Sciences's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Gilead Sciences's Market Cap
For the Drug Manufacturers - General subindustry, Gilead Sciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gilead Sciences's Market Cap Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Market Cap distribution charts can be found below:
* The bar in red indicates where Gilead Sciences's Market Cap falls into.
Gilead Sciences Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Gilead Sciences's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gilead Sciences (BUE:GILD) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Gilead Sciences Market Cap Related Terms
Thank you for viewing the detailed overview of Gilead Sciences's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BUE:GILD has been successfully added to your 